China Resources Pharmaceutical Group Yönetim
Yönetim kriter kontrolleri 3/4
China Resources Pharmaceutical Group CEO'su Xiaosong Bai, Jan2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı CN¥ 3.60M olup, şirket hissesi ve opsiyonları dahil olmak üzere 98.6% maaş ve 1.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.003% ine doğrudan sahiptir ve bu hisseler HK$ 1.03M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 4.1 yıldır.
Anahtar bilgiler
Xiaosong Bai
İcra Kurulu Başkanı
CN¥3.6m
Toplam tazminat
| CEO maaş yüzdesi | 98.6% |
| CEO görev süresi | 2.8yrs |
| CEO sahipliği | 0.003% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 4.1yrs |
Son yönetim güncellemeleri
Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥4b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥4m | CN¥4m | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥4b |
Tazminat ve Piyasa: Xiaosong 'ın toplam tazminatı ($USD 497.09K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 515.49K ).
Tazminat ve Kazançlar: Xiaosong 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Xiaosong Bai (53 yo)
2.8yrs
Görev süresi
CN¥3,601,000
Tazminat
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | CN¥3.60m | 0.0032% HK$ 1.0m | |
| VP & Executive Director | 3.2yrs | CN¥2.94m | Veri yok | |
| CFO & Executive Director | 1.4yrs | Veri yok | Veri yok | |
| Chief Information Officer & VP | 10.9yrs | Veri yok | Veri yok | |
| Company Secretary | less than a year | Veri yok | Veri yok | |
| Vice President | no data | Veri yok | Veri yok | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim: 3320 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | CN¥3.60m | 0.0032% HK$ 1.0m | |
| VP & Executive Director | 3.2yrs | CN¥2.94m | Veri yok | |
| CFO & Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | 8.4yrs | CN¥270.00k | Veri yok | |
| Non-Executive Director | 2.8yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 8.4yrs | CN¥270.00k | Veri yok | |
| Independent Non-Executive Director | 8.4yrs | CN¥270.00k | Veri yok | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.9yrs | Veri yok | Veri yok | |
| Non-Executive Director | 1.8yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 7.3yrs | CN¥270.00k | Veri yok | |
| Chairman | 5.1yrs | Veri yok | 0.0048% HK$ 1.6m | |
| Non-Executive Director | less than a year | Veri yok | Veri yok |
4.1yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 3320 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).